2024
Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history
Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Research And Treatment 2024, 1-6. PMID: 39602012, DOI: 10.1007/s10549-024-07560-y.Peer-Reviewed Original ResearchHigh-risk family historyFamily historyRare germline variantsCancer riskSNP-set kernel association testAssociated with breast cancer riskCancer casesContribution of family historyEarly-onset breast cancerCancer Prevention ClinicBreast cancerBreast cancer riskKernel association testBreast cancer casesCancer-predisposing genesGermline variantsGermline pathogenic variantsYoung womenPrevention clinicSKAT-OBurden testsPathogenic variantsExome sequencing dataAssociation TestLevel alterations
2022
The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients
Trant A, Chagpar A, Wei W, Neumeister V, Rimm D, Stavris K, Lurie B, Frederick C, Andrejeva L, Raghu M, Killelea B, Horowitz N, Lannin D, Knill-Selby E, Sturrock T, Hofstatter E. The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients. Integrative Cancer Therapies 2022, 21: 15347354221137290. PMID: 36444764, PMCID: PMC9716631, DOI: 10.1177/15347354221137290.Peer-Reviewed Original ResearchConceptsTumor volumeBlack cohoshSitu patientsDuctal carcinomaAnti-inflammatory effectsTumor cellular proliferationBreast cancer treatmentCellular proliferationWilcoxon signed-rank testDCIS patientsAdverse eventsEligible subjectsWindow trialsCore biopsyInvasive diseaseKi67 expressionSigned-rank testBreast cancerGrade 3Hormone changesPatientsQuantitative immunofluorescenceBC extractSignificant toxicityCancer treatment
2021
Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.
Afghahi A, Marsh S, Winchester A, Gao D, Parris H, Axell L, Ellisen L, Hofstatter E, Kurian A, Wood M, Zakalik D, Mullin C, Caswell-Jin J, Borges V, Tung N. Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study. Journal Of Clinical Oncology 2021, 39: 10531-10531. DOI: 10.1200/jco.2021.39.15_suppl.10531.Peer-Reviewed Original ResearchCHEK2 pathogenic variantsRecurrence scoreCase-control studyMedian RSBreast cancerPathogenic variantsHigh riskRisk groupsMutation statusHER2-negative BC patientsPR-negative breast cancerMulti-site case-control studyPatient-level clinical dataRS risk groupsLymph node statusHigh recurrence scoreLow-risk groupGermline pathogenic variantsSporadic breast cancerGenetic testing resultsElectronic medical recordsAdjuvant therapyChemotherapy benefitNode statusT stage
2019
Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago.
Parkinson G, Chagpar A, Alleyne-Mike K, Nunez-Smith M, Zhou A, Servais L, Hofstatter E. Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Journal Of Clinical Oncology 2019, 37: 6574-6574. DOI: 10.1200/jco.2019.37.15_suppl.6574.Peer-Reviewed Original ResearchFemale breast cancer patientsBreast cancer patientsNCCN criteriaCancer patientsGenetic counselingHigher breast cancer mortality ratesYounger ageHBOC testingBreast cancer mortality ratesOvarian cancer syndromeBreast cancer treatmentBreast cancer casesCancer mortality ratesYears of ageTesting servicesFurther genetic counselingPre-test counselingBreast cancer diagnosisNCCN guidelinesChart reviewFemale patientsOncology unitBreast cancerCancer casesFamily history
2018
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original Research
2017
Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.Peer-Reviewed Original ResearchPathologic complete response rateHER2-positive breast cancerDual HER2 blockadeComplete response ratePCR rateEstrogen receptorHER2 blockadeBreast cancerStage IResponse rateGrade 3/4 adverse eventsSymptomatic congestive heart failureClinical stage ICompletion of chemotherapyPhase II studyTaxane-based chemotherapyCongestive heart failureEfficacy of anthracyclinesPositive breast cancerNormal cardiac functionEntire treatment durationER- cancersER cohortNeoadjuvant pertuzumabWeekly paclitaxelComparison of epigenetic aging in normal breast tissue from women with and without breast cancer.
Hofstatter E, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Patwardhan G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. DOI: 10.1200/jco.2017.35.15_suppl.1522.Peer-Reviewed Original ResearchNormal breast tissueBreast cancerBreast tissueHealthy peersSusan G. Komen Tissue BankIU Simon Cancer CenterNormal breast tissue samplesBreast cancer preventionCohort of womenImportant risk factorKomen Tissue BankLifetime of womenBreast tissue samplesCurrent medicationsTumor characteristicsCancer CenterRisk factorsCancer preventionClinical dataFamily historyReduction mammoplastyHigh riskChronologic ageReproductive historyCancerManagement Strategies for Sexual Health After Breast Cancer Diagnosis
Overton E, Hofstatter E, Miller D, Ratner E. Management Strategies for Sexual Health After Breast Cancer Diagnosis. 2017, 303-322. DOI: 10.1007/978-3-319-42451-4_19.Peer-Reviewed Original ResearchEstrogen receptor-positive breast cancerReceptor-positive breast cancerModerate hot flashesPast medical historyLast menstrual periodBreast cancer diagnosisEndocrine therapyNight sweatsVaginal drynessVaginal symptomsHot flashesPainful intercourseMedical historyMenstrual periodBreast cancerSexual healthFemale presentsCancer diagnosisMonthsSignificant benefitsGabapentinTamoxifenTherapySymptomsCancer
2015
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.Peer-Reviewed Original Research
2014
Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.
Park E, Abu-Khalaf M, Hatzis C, LaSala J, Silber A, Hofstatter E, Sanft T, Russell R. Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer. Journal Of Clinical Oncology 2014, 32: e11501-e11501. DOI: 10.1200/jco.2014.32.15_suppl.e11501.Peer-Reviewed Original Research
2013
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
James E, Chung G, Sowers N, Clark M, Lilian R, Abraham G, Chmael S, Cappiello M, DiGiovanna M, Hofstatter E, Sanft T, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 154-154. DOI: 10.1200/jco.2013.31.26_suppl.154.Peer-Reviewed Original ResearchDose-expansion phaseGrade 3 non-hematological toxicityGrade 4 febrile neutropeniaCycle-1 DLTGrade 3 fatigueGrade 3/4 toxicitiesGrade 4 neutropeniaGrade 4 thrombocytopeniaMedian age 51Non-hematological toxicitiesObjective response rateAdvanced breast cancerDose-escalation phaseModest clinical activityHDAC inhibitor vorinostatClinical trial informationHistone deacetylase inhibitorsFebrile neutropeniaStable diseaseObjective responsePrior linesHematological toxicityTreatment delayClinical activityBreast cancerClinical experience with exemestane in postmenopausal women at increased risk of breast cancer.
Sorkin M, Lapolt D, Pusztai L, Hofstatter E. Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer. Journal Of Clinical Oncology 2013, 31: 1565-1565. DOI: 10.1200/jco.2013.31.15_suppl.1565.Peer-Reviewed Original ResearchCancer prevention clinicPostmenopausal womenPrevention clinicBreast cancerRetrospective chart reviewPoor patient acceptancePatient acceptance rateRisk of thrombosisCancer chemoprevention agentsBreast atypiaChemoprevention medicationsChemoprevention uptakeChart reviewEligible womenPatient characteristicsPrevention settingMedication uptakeMean ageChemoprevention agentsMedical historyUterine cancerPatient acceptanceFamily historyGeneral populationExemestaneA pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ.
Hofstatter E, Stavris K, Horowitz N, Killelea B, Tsangaris T, Lannin D, Andrejeva L, Cong X, Yao X, Rimm D, Chagpar A. A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ. Journal Of Clinical Oncology 2013, 31: tps1609-tps1609. DOI: 10.1200/jco.2013.31.15_suppl.tps1609.Peer-Reviewed Original ResearchIsopropanolic black cohosh extractBlack cohosh extractBlack cohoshDuctal carcinomaBreast cancerBreast epithelial cell proliferationPre-operative courseTwo-sided significance levelDisease-free survivalLiver function testsBreast cancer preventionSerum hormone levelsAnti-inflammatory effectsBreast cancer patientsPost-menopausal womenCohort of womenRecent preclinical dataSignificant protective effectKi-67 stainingBreast core biopsyLevels of Ki67Years of ageEpithelial cell proliferationWilcoxon signed-rank testEligible subjectsState of the Art in Imaging and Chemoprevention for High-Risk Patients
Hofstatter E, Andrejeva L, Chagpar A. State of the Art in Imaging and Chemoprevention for High-Risk Patients. Current Breast Cancer Reports 2013, 5: 125-133. DOI: 10.1007/s12609-013-0104-1.Peer-Reviewed Original ResearchBreast cancer preventionCancer preventionBreast cancerAccurate breast cancer risk assessmentAppropriate breast cancer screeningBreast cancer risk assessmentChemoprevention clinical trialsHigh-risk patientsBreast cancer screeningPromising new optionCancer risk assessmentCancer screeningClinical trialsPractical updatePatientsEarly detectionCancerPreventionNew optionsRiskRisk assessmentChemopreventionOptionsBreastClinicians